Changing focus in diabetes: From glucose to CV risk management

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Stephan Jacob, MD - Cardio Metabolic Institute, Villingen-Schwenningen, Germany

Prof. Jacob gives an overview of new antidiabetic interventions that showed a reduction in CV and total mortality in CV risk patients, which seems to be independent of improved glycemic control.

Video navigation menu

HbA1c and its associations 00:51
Is reducing HbA1c really successful? 02:16
Is there new hope with new agents? 04:49
Multifactorial effects of new antidiabetic treatments 06:37
Evolution of T2DM management 07:21

Educational information

This lecture was part of a CME accredited symposium: "Targeting SGLT2 in clinical cardiology: Exploring the benefits in CV Risk, Diabetes & Heart failure" during ESC 2018 in Munich, Germany.

Faculty

Prof Stephan Jacob, MD - endocrinologist/diabetologist, University of Tübingen and Cardio Metabolic Institute, Villingen-Schwenningen, Germany

Disclosures

This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

Funding

Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim/Lilly.

View slides of prof. Jacob

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.